Applicant : Nixon et al.
Serial No. : 10/783,311
Filed : February 19, 2004
Page : 2 of 13

Attorney's Docket No.: 10280-059001

Amendments to the Specification:

Insert the paper copy of the Sequence Listing filed herewith following the Drawings.

Note that, in the amendments below, double square brackets are used to show deletions, as required by the rules. **Single square brackets are part of the text of the application and do not represent any form of amendment.**

Replace the paragraph beginning at page 3, line 11 with the following rewritten paragraph:

In one embodiment, CDR1 of the LC variable region includes:

R-A-S-[QR]-[DGRS]-[VI]-[RSN]-[NRHST]-[YDEWNS]-[LVY]-[AGNL] (SEQ ID NO:358);

R-A-S-Q-X1-[VI]-X2-X3-[YDEWNS]-X4 (SEQ ID NO:359), wherein X1, X2, and X3 are any amino acid, e.g., a hydrophilic amino acid and X4 is hydrophobic, e.g., aliphatic;

X1-X2-X3-X4-X5-X6-X7-X8 (SEQ ID NO:392), wherein X1 is N, Q, R, or K, X2 is hydrophilic, A, or G, X3 is aliphatic, X4 and X5 are hydrophilic, X6 is any amino acid, or aromatic or hydrophilic, and X7 is hydrophobic;

S-G-S-S-S-N-I-[GEDA]-[SRV]-[NY]-[TLFD]-V-[YT] (SEQ ID NO:360);

S-G-S-S-S-N-I-[GEDA]-[SRV]-[ANY]-[TLFD]-V-[NYT] (SEQ ID NO:389);

T-G-T-S-S-D-[IV]-G-[DGY]-Y-[NED]-Y-V-S (SEQ ID NO:361);

T-G-T-S-S-D-[IV]-G-[ADGY]-Y-[NKED]-[YF]-V-S (SEQ ID NO:387);or

X1-X2-X3-G-X4-Y-X5-X6-X7-X8 (SEQ ID NO:393), wherein X1 is T or S, X2 is D or E, X3 is aliphatic, X4 is hydrophilic or G, and X5 is hydrophilic or N, E, D, or Q.

Replace the paragraph beginning at page 3, line 28 with the following rewritten paragraph:

In one embodiment, CDR2 of the LC variable region includes:

[ADEG]-[AVDNE]-[ASTNV]-[STNQ]-[LRN]-[AQPR]-[TFSKP] (SEQ ID NO:384);

Applicant : Nixon et al.
Serial No. : 10/783,311
Filed : February 19, 2004
Page : 3 of 13

Attorney's Docket No.: 10280-059001

[ADENG]-[AVDNE]-[ASTRNV]-[STENQ]-[LRN]-[AQPR]-[TFSKP]; (SEQ ID NO:385);

[ADE]-[AV]-[AST]-[ST]-[LR]-[AQ]-[TFSK] (SEQ ID NO:386);

[ST]-X1-X2-X3-[LRN]-[PRQ]-S (SEQ ID NO:382), wherein X1, X2, and X3 are hydrophilic;

[NST]-X1-X2-X3-[LRN]-[PRQ]-S (SEQ ID NO:388), wherein X1, X2, and X3 are hydrophilic;

[ST]-[DN]-[DN]-Q-R-P-S (SEQ ID NO:362);

[HST]-[DN]-[DN]-[QY]-R-P (SEQ ID NO: [[389]] 390); or

G-A-S-[ST]-[LR]-[QA] (SEQ ID NO:363).

Replace the paragraph beginning at page 4, line 8 with the following rewritten paragraph:

In one embodiment, CDR3 of the LC variable region includes:

[QL]-Q-X1-X2-X3-X4-P-X5 (SEQ ID NO:364), wherein X1, X2, X3, X4, and X5 are any amino acid, or X1 is hydrophilic, A, or G, X2 is hydrophilic, X3 is hydrophilic, X4 is aromatic, T, R, or K, X5 is hydrophobic, and the sequence can optionally be followed by T;

Q-Q-Y-X1-X2-X3-P-[PLR]-T (SEQ ID NO:365), wherein X1 and X2 are any amino acid, and X3 is hydrophobic (e.g., aromatic);

[AGQSV]-[ATS]-X1-X2-X3-[STGA]-X4-[STRG]-[GPNF]-X5-V (SEQ ID NO:381), wherein X2, X3, and X4 are any amino acid, and X1 is aromatic, or X2 is E, D, R, T, or S, X3 is D, N, Q, K, R, or S, and X4 is S, L, T, or N;

A-W-D-D-S-L-S-G-X1-V (SEQ ID NO:366), wherein X1 is hydrophobic;

A-W-D-D-S-L-S-G-[VW]-V (SEQ ID NO:367);

A-[AT]-W-D-[DNEQ]-[ST]-L-X1-G-X2-V (SEQ ID NO:391), wherein X1 is any amino acid (e.g., S, R, T, H, N) and X2 is any amino acid, e.g., hydrophobic, e.g., V, Y, or W; or

A-[AT]-W-D-[DNEQ]-[ST]-L-[SRT]-G-[VW]-V (SEQ ID NO:368).

Replace the paragraph beginning at page 5, line 10 with the following rewritten paragraph:

In one embodiment, CDR3 of the HC variable region includes:

D-F-G-S (SEQ ID NO:394);

at least two, three, or four consecutive tyrosines;

[SG]-[SG]-W-Y (SEQ ID NO:377);

S-S-[SG]-W-Y (SEQ ID NO:378),;

[RHWY]-Y-Y-Y-G-M (SEQ ID NO:379);

S-S-[SG]-W-[SY] (SEQ ID NO:383); or

[YSG]- [RHWY]-Y-Y-Y-G-M-D (SEQ ID NO:380).